PAX Health has acquired MAKRAF IME, adding a specialist network of licensed psychologists and neuropsychologists that supports independent medical examinations across New Jersey. Announced on July 17, 2026, the transaction expands PAX Health’s ability to provide psychology and neuropsychology evaluations for insurers, employers, attorneys and government agencies, although financial terms were not disclosed.
MAKRAF IME operates across 17 New Jersey counties and provides opinions addressing causality, treatment necessity, maximum medical improvement, permanency, disability and fitness for duty. These evaluations can materially influence workers’ compensation claims, disability determinations, employment decisions and legal disputes.
The acquisition therefore brings PAX Health more than additional clinical capacity. It adds an established referral infrastructure, statewide scheduling coverage and expertise in producing time-sensitive medical-legal reports that must withstand scrutiny from multiple parties.
For PAX Health, which is backed by HCAP Partners and funds managed by Hamilton Lane Incorporated, the deal reinforces a broader expansion strategy built around acquiring specialised behavioral healthcare practices and connecting them through a larger operating platform.
What does PAX Health gain by acquiring MAKRAF IME’s New Jersey examiner network?
The most immediate benefit is access to a specialist examiner network with coverage across most of New Jersey. Psychology and neuropsychology independent medical examinations cannot be scaled simply by opening more offices. The provider needs appropriately licensed clinicians with the experience to assess complex medical records, conduct testing, form defensible opinions and present findings clearly enough to support insurance or legal decisions.
MAKRAF IME brings that infrastructure into PAX Health. The practice has said its professionals are available across 17 counties and that its team has more than 40 years of high-level experience in its specialties. It also operates an online referral portal that enables clients to request and schedule examinations without relying entirely on telephone-based administration.
That combination of clinical expertise and referral workflow matters. In medical-legal services, a provider’s competitive position can depend as much on scheduling reliability, geographic convenience and report turnaround as on the examination itself. Delays can hold up claims, litigation and return-to-work decisions, giving referral partners a practical incentive to favour providers capable of coordinating cases consistently across a large territory.
PAX Health Chief Executive Officer Anthony DeSena indicated that MAKRAF IME had developed a reputation for evidence-based evaluations delivered within the timeframes expected by referral partners. His comments suggest that the acquisition is intended to strengthen both clinical capacity and operational execution.
Why is New Jersey an attractive market for behavioral health examination services?
New Jersey requires employers operating in the state, subject to applicable exemptions and federal programmes, to maintain workers’ compensation coverage or obtain approval to self-insure. That creates a broad institutional market involving employers, insurance carriers, claims administrators, medical professionals and legal advisers.
Independent medical examinations become particularly important when parties disagree over whether a medical condition resulted from employment, whether treatment remains necessary, whether maximum medical improvement has been reached or whether an individual can return to work. Psychological and neuropsychological cases add another layer of complexity because symptoms may involve trauma, depression, anxiety, cognitive impairment, chronic pain or the psychological consequences of a physical injury.
These cases require specialist expertise that may not be available through a general medical examination network. A statewide group capable of matching the case with an experienced psychologist or neuropsychologist can consequently hold a meaningful advantage.
The acquisition also gives PAX Health greater geographic density in a state where it already has substantial operating exposure. Density can shorten travel distances, increase appointment availability and allow cases to be allocated more efficiently among examiners. For insurers or attorneys managing multiple claims, a provider offering wider coverage under one administrative relationship may be more convenient than coordinating with numerous independent practices.
That convenience can support referral retention, but it does not eliminate competition. Large medical claims-management organisations offer broader national networks, while smaller specialist groups may compete on local reputation and individual examiner credentials. PAX Health will need to demonstrate that greater scale improves service without making the evaluation process feel standardised or impersonal.
How does MAKRAF IME fit the behavioral health platform PAX Health has assembled?
PAX Health was formed in 2024 by combining Behavioral Medicine Associates, Workers Compensation Psychological Network and Reservoir Health. Those businesses gave the platform exposure to psychological assessments, workers’ compensation-related behavioral healthcare, psychiatric evaluations, medication management and therapy.
The company continued expanding in 2025 through acquisitions including Harris Psychiatric Services, Richardson Psychiatric Associates and Neuropsychology and Counseling Associates. The acquired practices added workplace and accident-recovery psychiatry, broader outpatient mental healthcare in western Pennsylvania, clinical neuropsychology, dementia screening, cognitive training and forensic capabilities.
MAKRAF IME extends this strategy into a particularly specialised medical-legal segment. Workers Compensation Psychological Network already connected PAX Health with work-related psychological conditions, while Harris Psychiatric Services strengthened its ability to treat people experiencing psychiatric complications following workplace injuries and motor vehicle accidents. Neuropsychology and Counseling Associates added clinical and forensic neuropsychology.
The latest acquisition connects those capabilities with a dedicated statewide evaluation network. PAX Health is therefore assembling a platform that spans treatment, psychological testing, neuropsychology and medical-legal assessment rather than pursuing scale in a single outpatient service.
This broader model may improve the company’s ability to serve different customer groups. Patients require accessible clinical care, while employers, insurers, attorneys and agencies require timely expert evaluations and well-supported reports. Serving both markets can diversify referral sources and reduce dependence on any one reimbursement channel.
Where could the MAKRAF IME acquisition create operating leverage for PAX Health?
The most plausible efficiencies sit in administration rather than clinical decision-making. PAX Health may be able to centralise scheduling, credential verification, billing, records intake, information security, compliance and referral management while allowing psychologists and neuropsychologists to concentrate on examinations and reports.
A larger examiner network can also improve capacity utilisation. Cases can be matched according to speciality, location, availability and required turnaround time. If performed effectively, this reduces scheduling gaps and helps the platform accept referrals that a smaller practice might decline because the appropriate examiner is unavailable.
Commercially, MAKRAF IME introduces relationships with state agencies, employers, insurance companies and attorneys. These are potentially valuable institutional referral channels because one satisfied organisation may generate multiple cases over time. That gives medical-legal evaluation businesses a different growth profile from consumer-facing therapy practices, where patient acquisition can be more fragmented.
PAX Health may also be able to offer a wider combination of psychiatry, psychology and neuropsychology expertise when a referral involves complicated physical, psychological and cognitive issues. However, any cross-selling must be managed carefully. Clinical appropriateness and professional independence must determine provider selection, not the commercial interests of the wider platform.
MAKRAF IME co-founders Richard Filippone and Maryann Kezmarsky indicated that joining PAX Health should expand the practice’s ability to provide psychological opinions to its institutional clients while supporting further growth. Their continued involvement could help preserve referral relationships during the transition.
What integration risks could limit the value of PAX Health’s latest acquisition?
The most important risk concerns independence. An independent medical examiner is expected to provide an objective professional opinion, even when the examination has been requested and paid for by an insurer, employer, attorney or government organisation. PAX Health must ensure that commercial targets, referral volumes or other platform relationships do not influence clinical conclusions.
That requirement becomes more sensitive when the same corporate group operates both treatment businesses and independent evaluation services. Clear separation of records, clinical teams, referral processes and decision-making responsibilities will be essential. Even the appearance of a conflict could weaken confidence in an examiner’s opinion or create challenges during litigation.
Clinician retention is another risk. Specialist psychologists and neuropsychologists often represent the central value of an acquired practice. If integration introduces excessive administrative requirements, reduces professional autonomy or changes established working relationships, PAX Health could lose the expertise and reputation it intended to acquire.
Report quality must also remain consistent as volume grows. A late report is frustrating, but an inaccurate or poorly supported report can be considerably more damaging. Medical-legal documents may be examined by opposing experts, attorneys, insurers and courts, leaving little room for hurried conclusions or weak documentation.
The absence of disclosed financial terms creates an additional uncertainty. PAX Health has not revealed MAKRAF IME’s revenue, profitability, case volumes, examiner count or purchase multiple. The strategic logic is visible, but the financial return will depend on what PAX Health paid and how successfully it retains referrals after integration.
What does the acquisition signal about consolidation in behavioral healthcare services?
The PAX Health MAKRAF IME acquisition reflects a wider private equity strategy of combining specialised healthcare practices that may be difficult to scale independently. Many behavioral health businesses possess strong clinical reputations but lack the capital, technology and administrative infrastructure needed to expand across multiple regions.
A platform can provide those resources while preserving local expertise. Centralised compliance, recruitment, technology and finance functions can reduce duplicated costs, while acquisitions can introduce new services faster than building them internally.
The medical-legal evaluation market is especially suited to selective consolidation because it remains dependent on networks of individual specialists and long-established referral relationships. Acquiring a recognised local provider can give a platform immediate credibility that would take years to develop organically.
However, bigger does not automatically mean better. Referral partners will judge the combined business on appointment availability, examiner quality, turnaround time and the defensibility of its reports. PAX Health must show that consolidation improves those outcomes rather than merely increasing the number of businesses under its umbrella.
Competitors should view the deal as evidence that behavioural health platforms are moving into adjacent services with institutional demand and potentially repeatable referral economics. Regional practices with scarce clinical expertise, strong payer relationships or distinctive evaluation capabilities may consequently attract further acquisition interest.
How should investors interpret Hamilton Lane’s indirect exposure to the transaction?
PAX Health is privately held, and the MAKRAF IME acquisition does not provide a publicly traded pure-play investment opportunity. HCAP Partners remains the principal private equity sponsor, with funds managed by Hamilton Lane Incorporated participating in the platform’s backing.
Hamilton Lane Incorporated shares closed at $85.85 on July 17, down approximately 0.06% for the session. The stock nevertheless gained about 5.9% from its July 10 close of $81.09 and approximately 5.5% from $81.40 on June 17.
The recent rebound should be viewed against a much weaker longer-term position. At the July 17 close, Hamilton Lane Incorporated shares were roughly 46.7% below their 52-week high of $161.13, although they remained around 19.4% above the 52-week low of $71.88.
There was no discernible deal-specific share-price reaction, which is unsurprising. MAKRAF IME’s financial contribution was not disclosed, Hamilton Lane Incorporated is an indirect fund-level backer rather than the operating acquirer, and the transaction is unlikely to be material to an investment manager overseeing more than $1 trillion in assets under management and supervision.
For Hamilton Lane Incorporated investors, the company’s August 4 quarterly results, fundraising momentum, fee-related earnings and private-market deployment conditions will carry far greater weight. The PAX Health acquisition is better interpreted as evidence of continued portfolio-company activity than as a standalone public-market catalyst.
Can the MAKRAF IME acquisition become a durable growth driver for PAX Health?
Strategically, the acquisition looks coherent. MAKRAF IME strengthens an area where PAX Health already possesses relevant experience, adds geographic density in a core state and deepens the platform’s relationships with institutional referral sources.
The opportunity is to create a more efficient network capable of routing complex behavioral health examinations to qualified professionals while providing predictable scheduling and report delivery. If PAX Health can achieve that without compromising examiner independence, the transaction could improve referral retention and establish a stronger base for expansion into neighbouring markets.
The decisive evidence will come after integration. Referral volumes, report turnaround times, examiner retention, client renewal patterns and the ability to maintain professional credibility will determine whether the acquisition creates durable value.
PAX Health is steadily building a connected behavioral health platform rather than collecting unrelated practices. MAKRAF IME adds an important medical-legal layer to that strategy. The deal is modest in disclosed scale, but it offers a clear view of where private capital sees opportunity: specialised healthcare networks combining clinical scarcity, repeat institutional demand and operational infrastructure.
Key takeaways
- PAX Health has acquired MAKRAF IME, a specialist psychology and neuropsychology independent medical examination provider serving 17 New Jersey counties.
- MAKRAF IME conducts psychology examinations, neuropsychology examinations, disability evaluations, permanency assessments and fitness-for-duty evaluations.
- The acquisition broadens PAX Health’s exposure to business-to-business healthcare demand generated by insurance carriers, employers, attorneys and government agencies.
- MAKRAF IME complements PAX Health’s existing capabilities in workers’ compensation psychology, outpatient psychiatry, accident-related behavioral healthcare and forensic neuropsychology.
- The strategic value rests on geographic density, specialist availability, referral relationships and faster scheduling rather than conventional clinic expansion alone.
- Financial terms, revenue contributions, examiner numbers and expected acquisition synergies were not disclosed, limiting any firm assessment of the transaction’s valuation.
- Successful integration will depend on protecting examiner independence, maintaining report quality, retaining specialists and separating medical-legal evaluations appropriately from treatment services.